Pricing Climate Impacting Commercial Considerations

Estimated read time 1 min read

In this Pharmaceutical Executive video interview, Jesse Mendelsohn, senior vice president at Model N, talks about the influence of Medicare Part D drug price negotiations on manufacturer go-to-market strategies and decision-making, and the industry’s response to the wider dialogue on pricing transparency.

You May Also Like

More From Author

+ There are no comments

Add yours